Join Julia Charlton for a webinar on HKEX’s dedicated listing regime for pre-revenue biotech companies under Chapter 18A of the Main Board Listing Rules at 5:00pm-6:00pm on 4 February 2026.

This webinar is accredited with 1 CPD point by The Law Society of Hong Kong.

Register here >

About the Webinar

This comprehensive session covers: the definition of “Biotech Company”; suitability and eligibility criteria (including Core Product requirements, meaningful investment by sophisticated investor(s), working capital and public float requirements); enhanced listing document disclosure; existing shareholders’ participation; and post-listing continuing obligations.

Key highlights include:

• Why HKEX has become Asia’s leading biotech funding hub (78 Chapter 18A listings raising US$31B by Sept 2025, with 21 in the first 11 months of 2025)
• Recent enhancements: TECH channel for pre-application guidance, confidential filing option, and presumptions for WVR structures
• Detailed guidance on clinical trial and regulatory milestones for drugs, medical devices & other biotech products
• Listing document disclosures (risk factors, pipeline charts, cash burn rate, IP ownership, etc.)
• Ongoing obligations, notifiable transactions, stock marker “B”, requirement for HKEX consent for fundamental change to business, de-listing risks

• Enrolment is limited – registrations will be accepted on a first-come, first-served basis.
• Please note that we accept no liability for any non-availability for any CPD Point(s) for any participants whatsoever.